27/04/2026
On April 16, 2026, the FDA formally announced it is opening a pathway to expand testosterone therapy to men with idiopathic hypogonadism. Low testosterone. Real symptoms. No identified structural cause.
For years those men were told they didn't qualify. That just changed.
The existing approval covered only men with specific genetic or structural conditions. Everyone else was left outside the door to fend for themselves.
Countless numbers of guys were told their labs were fine. Told it was stress and just come back in six months. They went home and kept grinding through it. Kept blaming their schedule, their age, their life.
The FDA's own commissioner stated publicly that men have been "suffering from symptoms that significantly affect quality of life." That's straight from the mouth of the agency that sets the rules, finally admitting the rules failed the men who needed them most.
Keep in mind, this isn't a final approval. The process takes time. But for the man who sat in that office and was told he was 'fine' when he knew something was wrong, the door is finally opening.
Dr. Luis Lora Garcia, MD has always evaluated men on symptoms and labs together. Not just whether a number clears an arbitrary threshold.
That's always been the Telegenix standard. Medicine is finally catching up.
If you've been told you're fine and you know you're not, that conversation is worth having now.
Link in bio.
Sources: U.S. Food and Drug Administration. "FDA Takes Step Forward on Testosterone Therapy for Men." April 16, 2026. fda.gov | Federal Register, Docket No. FDA-2025-N-6743, April 20, 2026.
Not medical advice. Individual results vary. All treatments prescribed by licensed physicians after clinical evaluation.